Le Lézard
Classified in: Health
Subject: FDA

ABM RESPIRATORY CARE ANNOUNCES AN EXPANDED INDICATION FOR BIWAZE CLEAR


EAGAN, Minn., April 9, 2024 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel airway clearance and ventilation solutions, is excited to announce the expanded indication granted to the BiWaze® Clear System. The oscillating lung expansion (OLE) therapy of BiWaze Clear is intended to remove airway obstructions caused by retained secretions in the lower airways, as well as re-expand collapsed areas of the lungs, prevent respiratory tract infections, and enhance gas exchange and oxygenation. BiWaze Clear has now received FDA 510k clearance for use in-line with a ventilator in acute care environments.

This milestone presents acute care facilities with an innovative therapeutic option for ventilated patients suffering from atelectasis, retained secretions, or pneumonia. The inclusion of OLE therapy in-line with ventilators has demonstrated remarkable outcomes, including a 64% decrease in ventilator time and a 47% reduction in post-operative pulmonary complications among intubated patients.1

"This pivotal indication will greatly benefit our customers and patients," said Greg Miller, CEO at ABM Respiratory Care. "The expanded use of BiWaze Clear with ventilators underscores our commitment to continuously enhance patient care and highlights the versatility of our BiWaze platform."

BiWaze Clear initially received FDA 510k clearance in December 2022 for use with a face mask, mouthpiece, or trach adapter in acute and home care settings. This expanded indication further emphasizes ABM Respiratory Care's dedication to improving patient outcomes and advancing respiratory care.

About ABM Respiratory Care

Founded in 2017, ABM Respiratory Care is dedicated to advancing patient care by developing intelligent, clinically differentiated, and innovative respiratory care solutions to help people breathe better inside and outside the hospital. Our connected platform is designed to improve respiratory therapy by providing deeper breathing, improved oxygen exchange, reduce aerosol emission exposure, and communication for better disease management for people with compromised respiratory systems, in any care setting around the world. For more information visit, www.abmrc.com

1 Huynh TT, Liesching TN, Cereda M, Lei Y, Frazer MJ, Nahouraii MR, Diette GB, Efficacy of Oscillation and Lung Expansion in Reducing Postoperative Pulmonary Complication, Journal of the American College of Surgeons (2019)

Investor and Media Contact: 
Leah Noaeill
VP of Marketing and Clinical Affairs, ABM Respiratory Care
[email protected]
1.877.226.7201

SOURCE ABM Respiratory Care


These press releases may also interest you

at 21:30
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have...

at 21:20
The United States of America and ReNew Health Group LLC have settled a nursing home whistleblower claim involving allegations that the nursing home chain submitted false Medicare claims. We need transparency and accountability in our nursing homes....

at 20:00
The 5p- Society of North America, along with families and support organizations from over 95 countries, are bringing awareness of 5p Deletion Syndrome also known as 5p Minus (5p-)...

at 19:31
Alleva, a leading provider of electronic medical record (EMR) solutions, attended the first-ever East Coast TCIV conference last week in Palm Beach, Florida. The company's CEO, Steve McCall, Director of Sales, John David, and Manager of Strategic...

at 18:54
The Canadian Food Inspection Agency (CFIA) has confirmed the presence of emerald ash borer (EAB - Agrilus planipennis) in the City of Vancouver, British Columbia. These detections, which are outside of currently regulated areas for emerald ash borer...

at 18:35
Teva Pharmaceutical Industries Ltd. today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40...



News published on and distributed by: